Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1583-1594

  Zhang, X ^a   Maor, Y ^a   Wang, J F ^a   Kunos, G ^b   Groopman, J E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

angiogenesis; endocannabinoids; endothelial cells; G protein coupled receptor 55; VEGF C; wound healing

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; N ARACHIDONOYL SERINE; SERINE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ANGIOGENESIS; ARTICLE; ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; EMBRYO; ENDOTHELIUM; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CELL; WOUND HEALING;

ANIMALS; ARACHIDONIC ACIDS; CATTLE; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SERINE; WOUND HEALING;

EID: 77954334575     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00841.x     Document Type: Article

References (62)

1. Adams RH, Alitalo K (2007). Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464 478.
2. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ et al. (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870 879.
3. Albuquerque ML, Waters CM, Savla U, Schnaper HW, Flozak AS (2000). Shear stress enhances human endothelial cell wound closure in vitro. Am J Physiol Heart Circ Physiol 279:H293 H302.
4. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
5. Baker D, Pryce G, Davies WL, Hiley CR (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27:1 4.
6. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J et al. (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110:1996 2002.
7. Begg M, Mo FM, Offertaler L, Bátkai S, Pacher P, Razdan RK et al. (2003). G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem 278:46188 46194. (Pubitemid 37432770)
8. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM et al. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133 145.
9. Bellocchio L, Vicennati V, Cervino C, Pasquali R, Pagotto U (2007). The endocannabinoid system in the regulation of cardiometabolic risk factors. Am J Cardiol 100:7P 17P.
10. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urbán GM et al. (2007). Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316:1212 1216.
11. Berra E, Pagès G, Pouysségur J (2000). MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19:139 145.
12. Brown AJ (2007). Novel cannabinoid receptors. Br J Pharmacol 152:567 575.
13. Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA et al. (2000). Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 87:323 327.
14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946 1949.
15. Di Marzo V, Matias I (2005). Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585 589.
16. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA et al. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264:258 267.
17. Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E et al. (2007). Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 293:H3602 H3607.
18. Godlewski G, Offertáler L, Osei-Hyiaman D, Mo FM, Harvey-White J, Liu J et al. (2009). The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther 328:351 361.
19. Guo J, Williams DJ, Ikeda SR (2008). J Neurophysiol 100:1147 1151.
20. Guzmán M (2003). Cannabinoids: potential anticancer agents. Nat Rev Cancer 3:745 755.
21. 1 receptor. Proc Natl Acad Sci U S A 98:3662 3665.
22. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23:183 193.
23. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96:14136 14141.
24. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152:825 831.
25. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C (2002). Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55:619 625.
26. Klein TW (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400 411.
27. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105:2699 2704.
28. Lépicier P, Bibeau-Poirier A, Lagneux C, Servant MJ, Lamontagne D (2006). Signalling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci 102:155 166.
29. 2. Mol Pharmacol 73:441 450.
30. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A et al. (2008). Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11:152 159.
31. Man XY, Yang XH, Cai SQ, Bu ZY, Zheng M (2008). Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 12:649 660.
32. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84 88.
33. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S et al. (2006). N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103:2428 2433.
34. Mitchell CA, Davies MJ, Grounds MD, McGeachie JK, Crawford GJ, Hong Y et al. (1996). Enhancement of neovascularization in regenerating skeletal muscle by the sustained release of erucamide from a polymer matrix. J Biomater Appl 10:230 249.
35. 2 or EDG-1. Eur J Pharmacol 489:21 27.
36. Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8:885 895.
37. Nilsson K, Drmota T, Greasley PJ (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092 1101.
38. Offertáler L, Mo FM, Bátkai S, Liu J, Begg M, Razdan RK et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63:699 705.
39. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362:928 934.
40. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145:13 20.
41. Opitz CA, Rimmerman N, Zhang Y, Mead LE, Yoder MC, Ingram DA et al. (2007). Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells. FEBS Lett 581:4927 4931.
42. Pacher P, Haskó G (2008). Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153:252 262.
43. Pacher P, Bátkai S, Kunos G (2005). Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 168:599 625.
44. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389 462.
45. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M (2007). Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 211:495 503.
46. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D et al. (2004). Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15:4841 4853.
47. 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17:1771 1773.
48. 1 receptor. J Pharmacol Exp Ther 301:1020 1024.
49. Randall MD (2007). Endocannabinoids and the haematological system. Br J Pharmacol 152:671 675.
50. Ross RA (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30:156 163.
51. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092 1101.
52. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH et al. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64:193 198.
53. Stella N (2004). Cannabinoid signaling in glial cells. Glia 48:267 277.
54. Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773 778.
55. Wakamatsu K, Masaki T, Itoh F, Kondo K, Sudo K (1990). Isolation of fatty acid amide as an angiogenic principle from bovine mesentery. Biochem Biophys Res Commun 168:423 429.
56. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M et al. (2008). Integrin clustering enables anandamide-induced Ca2+ signalling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121:1704 1717.
57. Wang JF, Zhang X, Groopman JE (2001). Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J Biol Chem 276:41950 41957.
58. Wang H, Matsumoto H, Guo Y, Paria BC, Roberts RL, Dey SK (2003). Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc Natl Acad Sci U S A 100:14914 14919.
59. West DC, Thompson WD, Sells PG, Burbridge MF (2001). Angiogenesis Protocols: Angiogenesis Assays Using Chick Chorioallantoic Membrane, Murray JC (ed.) Human Press
60. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M et al. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129:437 453.
61. Zhang X, Wang JF, Kunos G, Groopman JE (2007). Cannabinoid modulation of Kaposi's sarcoma-associated herpesvirus infection and transformation. Cancer Res 67:7230 7237.
62. Zygmunt PM, Petersson J, Andersson DA, Chuang H, SørgÅrd M, Di Marzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452 457.